| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cytomx Therapeutics, Inc. (CTMX) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. CTMX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 987.9K | $3.95M | - | |
| Other | 650.0K | $2.60M | - | |
| CFO | 78.3K | $313.0K | - | |
| Other | 43.8K | $175.0K | - | |
| Dir | 38.0K | $152.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2025 | McCarthy Sean A.69 | CEO | Sell | 101,793 | $4.54 | $461,906.10 | -9.3% | +35.3% | - | |
| Jun 16, 2025 | Ogden Christopher52 | Chief Financial Officer | Sale+OE | 12,255 | $2.72 | $33,381.43 | -2.8% | -19.1% | - | |
| Jun 16, 2025 | Belvin Marcia51 | SVP, Chief Scientific Officer | Sale+OE | 13,884 | $2.69 | $37,334.08 | -4.9% | -19.1% | - | |
| Jun 16, 2025 | McCarthy Sean A.69 | CEO | Sale+OE | 55,511 | $2.69 | $149,263.53 | -4.8% | -19.1% | - | |
| Mar 18, 2025 | McCarthy Sean A.69 | CEO | Sell | 37,656 | $0.60 | $22,555.94 | -3.6% | +307.5% | +628.8% | |
| Mar 18, 2025 | Ogden Christopher52 | Chief Financial Officer | Sell | 8,551 | $0.60 | $5,122.05 | -4.1% | +307.5% | +628.8% | |
| Mar 18, 2025 | Chu Yu-Waye72 | Chief Medical Officer | Sell | 4,025 | $0.60 | $2,410.98 | -2.9% | +307.5% | +628.8% | |
| Mar 18, 2025 | Rowland Lloyd A50 | General Counsel | Sell | 10,203 | $0.60 | $6,111.60 | -7.8% | +307.5% | +628.8% | |
| Mar 18, 2025 | Belvin Marcia51 | SVP, Chief Scientific Officer | Sell | 19,512 | $0.60 | $11,687.69 | -7.3% | +307.5% | +628.8% | |
| Aug 20, 2024 | Landau Jeffrey B55 | Chief Business Officer | Sale+OE | 4,181 | $1.23 | $5,138.87 | -3.4% | -30.4% | +58.9% |